Ven­tyx sprints to Wall Street less than a year af­ter emerg­ing from stealth

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

It took sev­en months from ex­it­ing “qui­et mode” for Ven­tyx Bio­sciences to land its very own stock tick­er, rais­ing $165 mil­lion in ven­ture funds along the way.

Now, af­ter pric­ing a mas­sive $151.5 mil­lion IPO, the Encini­tas, CA-based biotech is gun­ning for Phase II.

Ven­tyx priced close to 9.5 mil­lion shares at $16 apiece on Wednes­day, the mid­point of its $15 to $17 range. CEO Ra­ju Mo­han filed the S-1 pa­pers at the end of Sep­tem­ber, just over a week af­ter un­veil­ing a $114 mil­lion Se­ries B round. He pen­ciled in the stan­dard fig­ure of $100 mil­lion at first, like­ly know­ing that in the last year, it’s been com­mon for biotechs to raise much more than those ini­tial es­ti­mates.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER